Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

• Status: Completed
• Trial end date: 2006-06-01

Summary

This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.

• Phase: Phase 4

Details

• Lead Sponsor: AstraZeneca; Pfizer
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Meropenem; Thienamycins